ClinicaliQ Trial Snapshot
- Optimising Colorectal Cancer Patient Pathways — Recruiting • Non-phase study • Oncology • NCT07430540.
- What is being tested: This trial optimises colorectal cancer patient pathways to improve early detection and survival outcomes through enhanced screening and diagnostic processes in Scotland.
- Patient eligibility overview: The study focuses on bowel cancer patients in Scotland, addressing the approximately 4,000 annual diagnoses and the population presenting with suspected or confirmed colorectal cancer across varying disease stages.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations. Improving the early detection of bowel cancer, and therefore survival, is important. The majority of bowel cancers are diagnosed within secondary-care (colorectal surgery unit). Upon GP referral to secondary-care, patients provide stool samples which are analysed for microscopic blood (FIT; faecal immunohistochemical test). Patients with a single positive result are more likely to have bowel cancer (0.2% risk if no blood detected,…
Eligibility Snapshot
- : * Patients referred to the NHS Lothian USoC CRC pathway or an urgent referral with 'red-flag' symptoms, and with a positive FIT on referral will be included. * Referred from start date of study, for up to 1 year
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.